Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

129.61USD
1:30am IST
Change (% chg)

$0.09 (+0.07%)
Prev Close
$129.52
Open
$129.51
Day's High
$131.10
Day's Low
$127.48
Volume
508,085
Avg. Vol
344,776
52-wk High
$143.22
52-wk Low
$100.20

Latest Key Developments (Source: Significant Developments)

Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences
Tuesday, 17 Apr 2018 

April 16 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES.BOSTON SCIENTIFIC CORP - SUCCESSFULLY OPPOSED EDWARDS LIFESCIENCES' EUROPEAN PATENT EP 2,399,550, RESULTING IN REVOCATION OF PATENT.BOSTON SCIENTIFIC - GERMAN COURT OF APPEAL TO HAVE HEARING IN MAY, JUNE THIS YEAR ABOUT CO'S PATENTS '254, '766 THAT EDWARDS WAS FOUND TO INFRINGE.  Full Article

Edwards Lifesciences Corp Says CEO Michael Mussallem's FY 2017 Total Compensation Was $10.8 Mln Vs $9.7 Mln In FY 2016
Friday, 30 Mar 2018 

March 29 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2017 TOTAL COMPENSATION WAS $10.8 MILLION VERSUS $9.7 MILLION IN FY 2016 - SEC FILING.  Full Article

Edwards Lifesciences Corp Acquires Harpoon Medical
Thursday, 7 Dec 2017 

Dec 6 (Reuters) - Edwards Lifesciences Corp ::EDWARDS ACQUIRES HARPOON MEDICAL.EDWARDS LIFESCIENCES CORP - EDWARDS PAID $100 MILLION IN CASH FOR HARPOON AT CLOSING ON DEC. 1.EDWARDS LIFESCIENCES - THERE IS POTENTIAL FOR UP TO $150 MILLION IN MILESTONE PAYMENTS OVER NEXT 10 YEARS AS PART OF DEAL.EDWARDS LIFESCIENCES - JAMES GAMMIE HAD AN EQUITY INTEREST IN HARPOON MEDICAL, AND WILL SERVE AS A CONSULTANT TO EDWARDS LIFESCIENCES.  Full Article

Edwards Lifesciences reports quarterly share of $0.79
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Edwards Lifesciences Corp ::Edwards Lifesciences - Qtrly earnings per share $0.79; Qtrly adjusted earnings per share $0.84; Qtrly sales $821.5 million, up 11.1 percent.Edwards Lifesciences - Qtrly Transcatheter Heart Valve Therapy sales of $481.2 million, up 17.3 percent.Q3 earnings per share view $0.86, revenue view $832.0 million -- Thomson Reuters I/B/E/S.Edwards lifesciences - Reaffirmed FY sales estimate at high end of $3.2 to $3.4 billion range, FY adjusted EPS estimate of $3.65 to $3.85.Edwards lifesciences - "Experienced minimal business impact" from recent natural disasters.FY2017 earnings per share view $3.78, revenue view $3.39 billion -- Thomson Reuters I/B/E/S.  Full Article

FDA approves expanded indication for Sapien XT and Sapien 3 transcatheter heart valves
Friday, 19 Aug 2016 

U.S. FDA : U.S. Food and Drug Administration today approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves .Requiring Edwards to conduct post-approval study to follow patients treated with either device in first,second clinical studies for 10 years.  Full Article

EDWARDS INTUITY Elite Rapid Deployment Valve receives FDA approval
Monday, 15 Aug 2016 

Edwards Lifesciences Corp :Edwards INTUITY Elite Rapid Deployment Valve receives FDA approval.  Full Article

Edwards Lifesciences Q2 Adjusted EPS $0.76
Wednesday, 27 Jul 2016 

Edwards Lifesciences Corp : Sees Q3 Sales Between $720 Mln - $760 Mln; Sees Q3 Adjusted Earnings Per Share Between $0.62 - $0.68 . Q3 Earnings Per Share View $0.64, Revenue View $708.1 Million; Fy2016 Earnings Per Share View $2.76, Revenue View $2.89 Billion -- Thomson Reuters I/B/E/S . Q2 Transcatheter Heart Valve Therapy Sales Of $418.6 Million, Up 48.7 Percent From Previous Year . Edwards Lifesciences Corp Q2 Earnings Per Share $0.58, Q2 Adjusted Earnings Per Share $0.76; Q2 Sales $759.3 Million, Up 23.1 Percent From Previous Year . Sees 2016 Total Sales At High End Of $2.7 Billion-$3.0 Billion; Sees 2016 Adjusted Earnings Per Share $2.78 - $2.88 .Q2 Earnings Per Share View $0.70, Revenue View $724.3 Million -- Thomson Reuters I/B/E/S.  Full Article

Edwards Lifesciences says jury returns verdict in favor of CardiAQ in case with Neovasc
Friday, 20 May 2016 

Edwards Lifesciences Corp : Federal jury in Boston returned a verdict in favor of CardiAQ in lawsuit filed against a former service provider, Neovasc . Jury awarded damages of $70 million for trade secret misappropriation ."Jury found that Neovasc breached non-disclosure agreement between parties, misappropriated CardiAQ's trade secrets".  Full Article

UPDATE 2-Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

April 24 Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc.